Candidemia has been considered a persistent public health problem with great impact on hospital costs and high mortality. We aimed to evaluate the epidemiology and prognostic factors of candidemia in a tertiary hospital in Northeast Brazil from January 2011 to December 2016. Demographic and clinical data of patients were retrospectively obtained from medical records and antifungal susceptibility profiling was performed using the broth microdilution method. A total of 68 episodes of candidemia were evaluated. We found an average incidence of 2.23 episodes /1000 admissions and a 30-day mortality rate of 55.9%. The most prevalent species were Candida albicans (35.3%), Candida tropicalis (27.4%), Candida parapsilosis (21.6%) and Candida glabrata (11.8%). Higher mortality rates were observed in cases of candidemia due to C . albicans (61.1%) and C . glabrata (100%), especially when compared to C . parapsilosis (27.3%). Univariate analysis revealed some variables which significantly increased the probability of death: older age ( P = 0.022; odds ratio [OR] = 1.041), severe sepsis ( P < 0.001; OR = 8.571), septic shock ( P = 0.035; OR = 3.792), hypotension ( P = 0.003; OR = 9.120), neutrophilia ( P = 0.046; OR = 3.080), thrombocytopenia ( P = 0.002; OR = 6.800), mechanical ventilation ( P = 0.009; OR = 8.167) and greater number of surgeries ( P = 0.037; OR = 1.920). Multivariate analysis showed that older age ( P = 0.040; OR = 1.055), severe sepsis ( P = 0.009; OR = 9.872) and hypotension ( P = 0.031; OR = 21.042) were independently associated with worse prognosis. There was no resistance to amphotericin B, micafungin or itraconazole and a low rate of resistance to fluconazole (5.1%). However, 20.5% of the Candida isolates were susceptible dose-dependent (SDD) to fluconazole and 7.7% to itraconazole. In conclusion, our results could assist in the adoption of strategies to stratify patients at higher risk for developing candidemia and worse prognosis, in addition to improve antifungal management.

No abstract

Vulvovaginal candidiasis (VVC) is one of the most common causes of vaginitis and affects about 75 % of women of reproductive age. In order to better understand the epidemiology and pathogenesis of this disease, we evaluated genetic relatedness among 62 clinical isolates of Candida albicans sequentially obtained from the anus and vagina of patients with sporadic and recurrent VVC. Evaluation of patients' demographic and clinical data, direct examination, and colony forming units (c.f.u.) counts of vaginal and anal samples were also performed. The genotypes of strains were determined with ABC genotyping and Randomly Amplified Polymorphic DNA (RAPD). Genotype A was the most prevalent (93.6 %), followed by genotype C (6.4 %), whereas genotype B was not found. We found the maintenance of the same ABC genotype, regardless of the body site of each patient. Most of the vaginal strains suffered microevolution, whereas most of the anal strains were replaced during the period of study. Vaginal and anal isolates of C. albicans obtained simultaneously from the same patient showed the same ABC genotype and high genetic similarity as determined by RAPD. Genotype A seemed to be dominant in both vaginal and anal isolates of patients with VVC. Our results corroborate the hypothesis that there are 'substrains' of the C. albicans vaginal clone successfully established, which dominate in an apparently random manner over the course of time. It is suggested that the anal reservoir constitutes a possible source for vaginal infection in most of the cases.

Cryptococcosis is an infectious disease of worldwide distribution, caused by encapsulated yeasts belonging to the phylum Basidiomycota. The genus Cryptococcus includes several species distributed around the world. The C. gattii/neoformans species complex is largely responsible for most cases of cryptococcosis. However, clinical series have been published of infections caused by Papiliotrema (Cryptococcus) laurentii and Naganishia albida (Cryptococcus albidus), among other related genera. Here, we examined the pathogenic potential and antifungal susceptibility of C. gattii/neoformans species complex (clades I and II) and related genera (Papiliotrema and Naganishia) isolated from environmental and clinical samples. P. laurentii (clade III), N. liquefasciens/N. albidosimilis (clade IV); and N. adeliensis/N. albida (clade V) strains produced higher levels of phospholipase and hemolysins, whereas the C. gattii/neoformans species complex strains (clades I and II) had markedly thicker capsules, produced more biofilm biomass and melanin, which are known virulence attributes. Interestingly, 40% of C. neoformans strains (clade II) had MICs above the ECV established for this species to amphotericin B. Several non-C. gattii/neoformans species complex (clades III to V) had MICs equal to or above the ECVs established for C. deuterogattii and C. neoformans for all the three antifungal drugs tested. Finally, all the non-C. gattii/neoformans clinical isolates (clades III to V) produced more melanin than the environmental isolates might reflect their particularly enhanced need for melanin during in vivo protection. It is very clear that C. gattii/neoformans species complex (clades I and II) strains, in general, show more similar virulence phenotypes between each other when compared to non-C. gattii/neoformans species complex (clades III to V) isolates. These observations together with the fact that P. laurentii and Naganishia spp. (clades III to V) strains were collected from the outside of a University Hospital, identify features of these yeasts important for environmental and patient colonization and furthermore, define mechanisms for infections with these uncommon pathogens.

No abstract

ResumoA capecitabina, medicamento antineoplásico de uso oral amplamente utilizado no tratamento de tumores colorretais e gástricos, embora opção terapêutica efetiva, apresenta altas taxas de toxicidade. O presente trabalho teve como objetivo correlacionar a variante genética rs1801133 da enzima metilenotetrahidrofolato redutase com a qualidade de vida anterior e posterior ao tratamento de pacientes em uso de capecitabina no Ambulatório de Oncologia do Hospital de Clínicas/UNICAMP. Foram incluídos 109 pacientes, predominantemente do sexo masculino, com média de idade de 58,61 ± 10,74. O genótipo foi determinado através da técnica de PCR-real time e a qualidade de vida avaliada por formulários que estão de acordo com os protocolos adotados pela European Organisation for Research and Treatment of Cancer, EORTC. Não foram observadas correlações entre a variante genética em questão e a qualidade de vida dos pacientes.